Leserbrief
Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection
Experimental Dermatology · 2026-05 · 35 (5)
DOI: 10.1111/exd.70257 ↗At a glance
Leserbrief in Experimental Dermatology, published online on 2026-04-29. Written by Guan-Kai Lai and 2 co-authors. Institution: School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. 5 references.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
Author keywords
COVID‐19baricitinibdermatomyositistranscriptional intermediary factor 1
Authors and institutions
- School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID profiles: Guan-Kai Lai, Chia-Yu Chu, Yung-Tsu Cho
Cite
APA
Lai, G. K., Chu, C. Y., & Cho, Y. T. (2026). Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection. Experimental Dermatology, 35(5). https://doi.org/10.1111/exd.70257
Vancouver
Lai GK, Chu CY, Cho YT. Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection. Experimental Dermatology. 2026;35(5). doi:10.1111/exd.70257
BibTeX
@article{Lai2026,
author = {Lai, Guan-Kai and Chu, Chia-Yu and Cho, Yung-Tsu},
title = {Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection},
journal = {Experimental Dermatology},
year = {2026},
volume = {35},
number = {5},
doi = {10.1111/exd.70257}
}
EUVIMED